NASDAQ:SVRA - Savara Stock Price, Price Target & More

$8.63 -0.32 (-3.58 %)
(As of 04/26/2018 09:24 AM ET)
Previous Close$8.95
Today's Range$8.57 - $8.98
52-Week Range$4.60 - $17.19
Volume123,000 shs
Average Volume160,727 shs
Market Capitalization$273.91 million
P/E Ratio-4.90
Dividend YieldN/A
Beta0.04

About Savara (NASDAQ:SVRA)

Savara logoSavara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Receive SVRA News and Ratings via Email

Sign-up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SVRA
CUSIPN/A
Phone512-961-1891

Debt

Debt-to-Equity Ratio0.13%
Current Ratio16.28%
Quick Ratio16.28%

Price-To-Earnings

Trailing P/E Ratio-4.90
Forward P/E Ratio-6.03
P/E GrowthN/A

Sales & Book Value

Annual Sales$130,000.00
Price / Sales2,031.37
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book2.21

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-29,790,000.00
Net MarginsN/A
Return on Equity-45.53%
Return on Assets-30.28%

Miscellaneous

Employees24
Outstanding Shares30,600,000

How to Become a New Pot Stock Millionaire

Savara (NASDAQ:SVRA) Frequently Asked Questions

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) released its earnings results on Wednesday, March, 14th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. View Savara's Earnings History.

What price target have analysts set for SVRA?

5 analysts have issued 12-month price targets for Savara's shares. Their forecasts range from $20.00 to $35.00. On average, they expect Savara's share price to reach $26.40 in the next twelve months. View Analyst Ratings for Savara.

What are Wall Street analysts saying about Savara stock?

Here are some recent quotes from research analysts about Savara stock:
  • 1. According to Zacks Investment Research, "Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. " (11/23/2017)
  • 2. Canaccord Genuity analysts commented, "We see Savara’s work in NTM as meaningfully differentiated from other therapies as Molgradex is a non- antibiotic approach to treating lung NTMs and the product has potential to show efficacy in especially-hard-to-treat MABS infections where there are no viable pharmacological therapies available." (10/30/2017)

Who are some of Savara's key competitors?

Who are Savara's key executives?

Savara's management team includes the folowing people:
  • Robert N. Neville, Chairman of the Board, Chief Executive Officer (Age 51)
  • Taneli Jouhikainen, President, Chief Operating Officer (Age 51)
  • David L. Lowrance, Chief Financial Officer (Age 50)
  • Nevan C. Elam, Independent Director (Age 49)
  • Richard J. Hawkins, Independent Director (Age 68)
  • Joseph S. McCracken Ph.D., Independent Director (Age 64)
  • Matthew Pauls J.D., Independent Director (Age 46)
  • Yuri Pikover, Independent Director (Age 56)

Has Savara been receiving favorable news coverage?

Media coverage about SVRA stock has been trending somewhat positive on Thursday, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Savara earned a media sentiment score of 0.15 on Accern's scale. They also gave media coverage about the company an impact score of 45.34 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Savara?

Shares of SVRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $8.63.

How big of a company is Savara?

Savara has a market capitalization of $273.91 million and generates $130,000.00 in revenue each year. The company earns $-29,790,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Savara employs 24 workers across the globe.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, Austin TX, 78746. The company can be reached via phone at 512-961-1891 or via email at [email protected]


MarketBeat Community Rating for Savara (SVRA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Savara and other stocks. Vote "Outperform" if you believe SVRA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVRA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Savara (NASDAQ:SVRA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Savara in the last 12 months. Their average twelve-month price target is $26.40, suggesting that the stock has a possible upside of 205.91%. The high price target for SVRA is $35.00 and the low price target for SVRA is $20.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.40$26.40$26.40$24.50
Price Target Upside: 205.91% upside107.87% upside77.54% upside167.18% upside

Savara (NASDAQ:SVRA) Consensus Price Target History

Price Target History for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/9/2018Canaccord GenuitySet Price TargetBuy$25.00HighView Rating Details
1/3/2018Ladenburg ThalmannInitiated CoverageBuy -> Buy$35.00MediumView Rating Details
10/31/2017Roth CapitalLower Price TargetBuy$40.00 -> $32.00N/AView Rating Details
9/22/2017Jefferies GroupInitiated CoverageBuy -> Buy$20.00HighView Rating Details
9/11/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$20.00HighView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Savara (NASDAQ:SVRA) Earnings History and Estimates Chart

Earnings by Quarter for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.32)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.31)($0.31)($0.31)
Q2 20181($0.33)($0.33)($0.33)
Q3 20181($0.32)($0.32)($0.32)
Q4 20181($0.36)($0.36)($0.36)

Savara (NASDAQ SVRA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018Q4 2017($0.2520)($0.23)ViewListenView Earnings Details
11/8/2017Q3 2017($0.40)($0.28)ViewN/AView Earnings Details
8/9/2017Q2 2017($0.90)ViewN/AView Earnings Details
5/9/2017Q1 2017($1.61)ViewN/AView Earnings Details
3/6/2017Q4 2016($2.10)($1.40)$0.08 millionViewN/AView Earnings Details
11/8/2016Q3 2016($3.50)($2.80)$0.05 millionViewN/AView Earnings Details
8/9/2016Q2 2016($4.20)($3.50)ViewN/AView Earnings Details
5/6/2016Q1 2016($4.90)($4.20)ViewN/AView Earnings Details
3/14/2016Q4 2015($3.50)($4.20)ViewN/AView Earnings Details
11/12/2015Q3 2015($3.50)($4.20)ViewN/AView Earnings Details
8/12/2015Q2 2015($2.80)($4.20)ViewN/AView Earnings Details
5/11/2015Q1 2015($2.80)($4.20)ViewN/AView Earnings Details
3/24/2015Q4 2014($3.50)ViewN/AView Earnings Details
10/31/2014Q3 2014($4.20)ViewN/AView Earnings Details
8/11/2014Q2 2014($4.20)ViewN/AView Earnings Details
5/5/2014Q1 2014($4.20)ViewN/AView Earnings Details
3/26/2014Q4 2013($4.20)ViewN/AView Earnings Details
11/4/2013Q3 2013($3.50)ViewN/AView Earnings Details
8/5/2013Q2 2013($6.29)ViewN/AView Earnings Details
5/15/2013Q1 2013($8.39)ViewN/AView Earnings Details
3/19/2013Q4 2012($9.09)($5.59)ViewN/AView Earnings Details
11/5/2012Q3 2012($6.29)($4.90)ViewN/AView Earnings Details
8/6/2012Q2 2012($5.87)ViewN/AView Earnings Details
5/7/2012Q1 2012($6.08)ViewN/AView Earnings Details
3/7/2012Q4 2011($6.29)($6.57)ViewN/AView Earnings Details
11/7/2011Q3 2011($9.09)($8.39)ViewN/AView Earnings Details
8/8/2011Q2 2011($9.09)($8.39)ViewN/AView Earnings Details
5/9/2011Q1 2011($18.18)($9.09)ViewN/AView Earnings Details
3/10/2011Q4 2010($11.89)($10.70)ViewN/AView Earnings Details
11/8/2010Q3 2010($23.08)($8.74)ViewN/AView Earnings Details
8/6/2010Q2 2010($35.66)($27.34)ViewN/AView Earnings Details
4/30/2010Q1 2010($33.92)ViewN/AView Earnings Details
3/16/2010Q4 2009($69.93)ViewN/AView Earnings Details
11/10/2009Q3 2009($40.21)ViewN/AView Earnings Details
8/12/2009Q2 2009($71.68)ViewN/AView Earnings Details
5/12/2009Q1 2009($61.19)ViewN/AView Earnings Details
3/25/2009Q4 2008($145.10)ViewN/AView Earnings Details
11/6/2008Q3 2008($132.87)ViewN/AView Earnings Details
8/11/2008Q2 2008($124.13)ViewN/AView Earnings Details
5/12/2008Q1 2008($115.38)ViewN/AView Earnings Details
3/13/2008Q4 2007($87.41)($104.90)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Savara (NASDAQ:SVRA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Savara (NASDAQ SVRA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.93%
Institutional Ownership Percentage: 38.13%
Insider Trading History for Savara (NASDAQ:SVRA)
Institutional Ownership by Quarter for Savara (NASDAQ:SVRA)

Savara (NASDAQ SVRA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Yuri PikoverDirectorBuy3,734$9.00$33,606.00153,734View SEC Filing  
2/15/2018David L LowranceCFOSell7,000$12.88$90,160.0033,994View SEC Filing  
2/15/2018Jaakko Taneli JouhikainenInsiderSell25,000$12.85$321,250.00219,216View SEC Filing  
10/27/2017Yuri PikoverDirectorBuy50,000$7.85$392,500.00150,000View SEC Filing  
6/7/2017David L LowranceCFOBuy2,100$4.75$9,975.002,100View SEC Filing  
6/7/2017Jaakko Taneli JouhikainenInsiderBuy10,500$4.75$49,875.00235,326View SEC Filing  
6/7/2017Joseph S MccrackenDirectorBuy52,250$4.75$248,187.5059,866View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Savara (NASDAQ SVRA) News Headlines

Source:
DateHeadline
Savara (SVRA) Upgraded to "Sell" by BidaskClubSavara (SVRA) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 12 at 10:21 AM
 Brokerages Anticipate Savara Inc (SVRA) to Post -$0.31 EPS Brokerages Anticipate Savara Inc (SVRA) to Post -$0.31 EPS
www.americanbankingnews.com - April 11 at 7:18 PM
Savara (SVRA) Given a $25.00 Price Target by Canaccord Genuity AnalystsSavara (SVRA) Given a $25.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - April 10 at 7:31 AM
Savara Inc (SVRA) Given Consensus Recommendation of "Hold" by BrokeragesSavara Inc (SVRA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 3:36 PM
Savara (SVRA) Given New $32.00 Price Target at Roth CapitalSavara (SVRA) Given New $32.00 Price Target at Roth Capital
www.americanbankingnews.com - April 2 at 8:04 PM
Savara Inc (SVRA) Director Yuri Pikover Buys 3,734 SharesSavara Inc (SVRA) Director Yuri Pikover Buys 3,734 Shares
www.americanbankingnews.com - April 2 at 1:22 PM
Savara (SVRA) Lowered to "Buy" at BidaskClubSavara (SVRA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 2:18 PM
BidaskClub Downgrades Savara (SVRA) to Strong SellBidaskClub Downgrades Savara (SVRA) to Strong Sell
www.americanbankingnews.com - March 30 at 11:06 AM
Report: Exploring Fundamental Drivers Behind Mast Therapeutics, Pebblebrook Hotel Trust, Smart, Waddell & Reed Financial, Quality Care Properties, and Meridian Waste Solutions — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Mast Therapeutics, Pebblebrook Hotel Trust, Smart, Waddell & Reed Financial, Quality Care Properties, and Meridian Waste Solutions — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - March 30 at 8:14 AM
Savara Inc to Post FY2019 Earnings of ($1.96) Per Share, Jefferies Group Forecasts (SVRA)Savara Inc to Post FY2019 Earnings of ($1.96) Per Share, Jefferies Group Forecasts (SVRA)
www.americanbankingnews.com - March 19 at 7:46 AM
Equities Analysts Issue Forecasts for Savara Incs Q1 2018 Earnings (SVRA)Equities Analysts Issue Forecasts for Savara Inc's Q1 2018 Earnings (SVRA)
www.americanbankingnews.com - March 16 at 7:56 AM
Savara (SVRA) Posts  Earnings Results, Beats Expectations By $0.02 EPSSavara (SVRA) Posts Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - March 15 at 2:24 PM
Savaras (SVRA) CEO Robert Neville on Q4 2017 Results - Earnings ... - Seeking AlphaSavara's (SVRA) CEO Robert Neville on Q4 2017 Results - Earnings ... - Seeking Alpha
seekingalpha.com - March 15 at 8:09 AM
Savara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20thSavara to Present at 28th Annual Oppenheimer & Co. Healthcare Conference on March 20th
finance.yahoo.com - March 15 at 8:09 AM
Savara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateSavara Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
feeds.benzinga.com - March 14 at 4:55 PM
Savara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung InfectionSavara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection
www.streetinsider.com - March 13 at 7:23 PM
Savara Misses Endpoint, Stocks TankSavara Misses Endpoint, Stocks Tank
www.baystreet.ca - March 13 at 7:23 PM
Savara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection - StreetInsider.comSavara (SVRA) Initiates Phase 2a Clinical Study of Molgradex for Treatment of NTM Lung Infection - StreetInsider.com
www.streetinsider.com - March 13 at 8:16 AM
Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung InfectionSavara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection
finance.yahoo.com - March 13 at 8:16 AM
Savara Misses Endpoint, Stock TanksSavara Misses Endpoint, Stock Tanks
www.baystreet.ca - March 12 at 6:45 PM
Savara Inc (NASDAQ:SVRA): When Will It Breakeven?Savara Inc (NASDAQ:SVRA): When Will It Breakeven?
finance.yahoo.com - March 12 at 6:45 PM
The Week Ahead In Biotech: Earnings, PDUFA Dates And More ... - BenzingaThe Week Ahead In Biotech: Earnings, PDUFA Dates And More ... - Benzinga
www.benzinga.com - March 12 at 8:28 AM
Savara : Aironite Fails To Meet Primary Endpoint In Indie Phase 2 Study - NasdaqSavara : Aironite Fails To Meet Primary Endpoint In Indie Phase 2 Study - Nasdaq
www.nasdaq.com - March 12 at 8:28 AM
SVRA Disappoints, SNY/REGNs Praluent Price To Be Cut, OBSV On Watch - NasdaqSVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch - Nasdaq
www.nasdaq.com - March 12 at 8:28 AM
Savara (SVRA) Says Aironite Fails to Meet Primary Endpoint in Indie Phase 2 Clinical Study (Earlier) - StreetInsider.comSavara (SVRA) Says Aironite Fails to Meet Primary Endpoint in Indie Phase 2 Clinical Study (Earlier) - StreetInsider.com
www.streetinsider.com - March 12 at 8:28 AM
Aironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research NetworkAironite Fails to Meet Primary Endpoint in the Indie Phase 2 Clinical Study Conducted by the Heart Failure Clinical Research Network
finance.yahoo.com - March 12 at 8:28 AM
Savara Inc (SVRA) Receives Average Rating of "Hold" from BrokeragesSavara Inc (SVRA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 11 at 5:55 PM
Calithera Biosciences (CALA) vs. Savara (SVRA) Head-To-Head AnalysisCalithera Biosciences (CALA) vs. Savara (SVRA) Head-To-Head Analysis
www.americanbankingnews.com - March 8 at 5:55 AM
Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018Savara to Host Fourth Quarter & Fiscal Year End 2017 Financial Results and Business Update Conference Call on Wednesday March 14, 2018
finance.yahoo.com - March 7 at 8:11 AM
Sectoral Asset Management Inc Invests $2.37 Million in Savara Inc (SVRA) StockSectoral Asset Management Inc Invests $2.37 Million in Savara Inc (SVRA) Stock
www.americanbankingnews.com - March 6 at 2:11 PM
VHCP Management II LLC Buys Shares of 1,259,500 Savara Inc (SVRA)VHCP Management II LLC Buys Shares of 1,259,500 Savara Inc (SVRA)
www.americanbankingnews.com - March 6 at 10:50 AM
Savara (SVRA) Rating Lowered to Strong Sell at ValuEngineSavara (SVRA) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 4 at 3:04 PM
Brown Advisory Inc. Purchases New Holdings in Savara Inc (SVRA)Brown Advisory Inc. Purchases New Holdings in Savara Inc (SVRA)
www.americanbankingnews.com - March 2 at 5:08 AM
BidaskClub Lowers Savara (SVRA) to SellBidaskClub Lowers Savara (SVRA) to Sell
www.americanbankingnews.com - February 24 at 11:18 AM
Savara Inc (SVRA) CFO David L. Lowrance Sells 7,000 SharesSavara Inc (SVRA) CFO David L. Lowrance Sells 7,000 Shares
www.americanbankingnews.com - February 20 at 11:00 AM
Savara Inc (SVRA) Insider Jaakko Taneli Jouhikainen Sells 25,000 SharesSavara Inc (SVRA) Insider Jaakko Taneli Jouhikainen Sells 25,000 Shares
www.americanbankingnews.com - February 20 at 9:40 AM
Top Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11thTop Line Results From Aironite Phase 2 Clinical Trial for the Treatment of HFpEF to Be Presented at American College of Cardiology 67th Annual Scientific Sessions & Expo on March 11th
finance.yahoo.com - February 16 at 8:13 AM
Investors Are Undervaluing Savara Inc (NASDAQ:SVRA) By 38.56%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing Savara Inc (NASDAQ:SVRA) By 38.56%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - February 15 at 5:24 PM
ValuEngine Upgrades Savara (SVRA) to "Sell"ValuEngine Upgrades Savara (SVRA) to "Sell"
www.americanbankingnews.com - February 14 at 11:12 PM
Savara Inc (SVRA) Receives Average Rating of "Buy" from BrokeragesSavara Inc (SVRA) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 14 at 3:26 PM
BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.BRIEF-Savara Announces IND Approval For Expansion Of Molgradex Phase 3 Study Into U.S.
www.reuters.com - February 12 at 9:06 AM
Savara (SVRA) Raised to Hold at BidaskClubSavara (SVRA) Raised to Hold at BidaskClub
www.americanbankingnews.com - February 10 at 8:50 AM
Contrasting Proteon Therapeutics (PRTO) & Savara (SVRA)Contrasting Proteon Therapeutics (PRTO) & Savara (SVRA)
www.americanbankingnews.com - February 9 at 5:34 PM
Savara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous MycobacteriaSavara Reports Publication of Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria
finance.yahoo.com - February 6 at 8:49 AM
Savara to Present at the 20th Annual BIO CEO & Investor Conference on February 12thSavara to Present at the 20th Annual BIO CEO & Investor Conference on February 12th
finance.yahoo.com - February 5 at 8:58 AM
Research Report Identifies Casella Waste, Savara Inc., Maximus, PCM, FARO Technologies, and Granite Point Mortgage Trust with Renewed Outlook Fundamental Analysis, Calculating Forward MovementResearch Report Identifies Casella Waste, Savara Inc., Maximus, PCM, FARO Technologies, and Granite Point Mortgage Trust with Renewed Outlook Fundamental Analysis, Calculating Forward Movement
finance.yahoo.com - January 30 at 8:46 AM
Mast Therapeutics (SVRA) Stock Rating Lowered by BidaskClubMast Therapeutics (SVRA) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - January 27 at 1:46 PM
BidaskClub Downgrades Mast Therapeutics (SVRA) to HoldBidaskClub Downgrades Mast Therapeutics (SVRA) to Hold
www.americanbankingnews.com - January 21 at 1:34 PM
Mast Therapeutics, Inc. (SVRA) Given Consensus Rating of "Buy" by BrokeragesMast Therapeutics, Inc. (SVRA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 20 at 3:52 PM
Mast Therapeutics (SVRA) Coverage Initiated at Ladenburg Thalmann Financial ServicesMast Therapeutics (SVRA) Coverage Initiated at Ladenburg Thalmann Financial Services
www.americanbankingnews.com - January 3 at 10:58 AM

SEC Filings

Savara (NASDAQ:SVRA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Savara (NASDAQ:SVRA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Savara (NASDAQ SVRA) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.